The primary endpoint is progression free survival (PFS) defined as the time between randomization and the first evidence of progressive disease or date of death, whichever occurs first. Documentation of disease progression will be defined as per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria based on investigator assessment. The censoring date for a patient who is known to be progression-free would be the date of the last tumor assessment.